3[3]Gagliardi MC,Sallusto F,Marinaro M,et al.Effects of the adjuvant cholera toxin on dendritic cells:stimulatory and inhibitory signals that result in the amplification of immune responses[J].Int J Med Microbiol 2002,291:571-575.
4[4]Lavelle EC,McNeela E,Armstrong ME,et al.Cholera toxin promotes the induction of regulatory T cells specific for bystander antigens by modulating dendritic cell activation[J].J Immunol 2003,171 (5):2384-2392.
5[5]Cheng E,Cordenas-Freytag I,Clements JD.The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT)[J].Vaccine 2000,18(1-2):38-49.
6[6]Lomada D,Gambhira R,Nehete PN,et al.A two-codon mutant of cholera toxin lacking ADP-ribosylating activity functions as an effective adjuvant for eliciting mucosal and systemic cellular immune responses to peptide antigens[J].Vaccine 2004,23(4):555-565.
8[8]Fujihashi K,Koga T,Ginkel FW,et al.A dilemma for mucosal vaccination:efficacy versus toxicity using enterotoxin-based adjuvants[J].Vaccine 2002,20(19-20):2431-2438.
9[9]Munro P,Flatau G,Anjuere2 F,et al.The Rho GTPase activators CNF1 and DNT bacterial toxins have mucosal adjuvant properties[J].Vaccine 2005,23(20):2551-2556.
10[10]Moreno-fierros L,Ruiz-Medina EJ,Esquivel R,et al.Intranasal Cry1Ac protoxin is an effective mucosal and systemic carrier and adjuvant of Streptococcus pneumoniae polysaccharides in mice[J].Scand J Immunol 2003,57:45-55.
